Equity markets saw pronounced sector- and company-specific movements on Monday. Semiconductor and optical-equipment names posted some of the strongest advances, while several large financial and media companies recorded declines. Momentum was also pronounced among mid- and small-cap biotech stocks following trial updates and corporate financing activity.
Mega-cap movers (Market Cap: $200B+)
- Avago Technologies (AVGO) +3.79%
- GE Vernova LLC (GEV); Rothschild Redburn upgrades GE Vernova stock rating on AI demand +2.63%
- Lam Research Corp (LRCX) +2.38%
- At&t (T); Telus to redeem C$500M of 2.75% notes due July 2026 -3.21%
- Oracle Corp (ORCL) -3.17%
- Home Depot (HD) -2.87%
- IBM (IBM) -2.25%
- Cisco Sys Inc (CSCO) -3.54%
- Bank Of America (BAC) -3.26%
- Wells Fargo (WFC) -4.07%
Within the largest market-cap cohort, chipmakers and technology suppliers outperformed, while several legacy tech and major banking names moved lower. A corporate note redemption tied to Telus was flagged alongside the AT&T listing.
Large-cap movers (Market Cap: $10B-$200B)
- Lumentum Holdings Inc (LITE) +10.84%
- Bloom Energy Corp (BE) +8.6%
- GS Acquisition A (VRT) +8.0%
- United Therapeutics Corp (UTHR); United Therapeutics authorizes $2 billion buyback program +7.5%
- Circle Internet Group Inc (CRCL) +7.4%
- SanDisk Corp-Exch (SNDK) +6.31%
- Dow Chemical (DOW); RBC Capital upgrades Dow stock rating on margin upside outlook +5.72%
- Xpeng Inc (XPEV) +5.98%
- Amark Preci (GOLD) -6.05%
- Viacom Cl B (PSKY) -7.51%
Among large-cap stocks, Lumentum led gains. The list also included companies with analyst upgrades and a notable share-repurchase authorization, both of which were explicitly reported alongside price moves.
Mid-cap movers (Market Cap: $2B-$10B)
- Xenon Pharmaceuticals (XENE); Xenon’s epilepsy drug azetukalner meets Phase 3 trial goals +45.12%
- Oaktree Acquisition Corp (HIMS); Needham upgrades Hims and Hers stock rating on Novo partnership +41.93%
- Magenta Therapeutics (DNTH); Dianthus Therapeutics stock surges 25% on positive trial data +18.77%
- Kingsoft Cloud Holdings Ltd (KC) +18.1%
- Dynergy (DYN) +14.17%
- Tessera Tech (ADEA); Adeia reaches licensing deal with AMD, settles litigation +9.16%
- Cantor Equity Partners Class A (XXI) +9.89%
- National HealthCare Corp (NHC) -7.83%
- ELF Beauty Inc (ELF) -8.56%
- Evolution Metals Tech (EMAT) -13.22%
Mid-cap moves were dominated by biotech and health-related news, with Xenon reporting Phase 3 results and other names moving on trial- or partnership-related developments. Semiconductor-related licensing and legal settlements were also noted.
Small-cap movers (Market Cap: $300M-$2B)
- Relmada Therapeutics (RLMD); Relmada Therapeutics secures $160M in PIPE financing +49.55%
- Uniqure Nv (QURE); RBC upgrades uniQure stock on FDA leadership change, raises target to $35 +19.83%
- Regenxbio Inc (RGNX) +16.42%
- Solid Biosciences (SLDB) +16.37%
- Hyperliquid Strategies (PURR) +17.78%
- Lyell Immunopharma (LYEL); Citizens initiates Lyell Immunopharma stock at outperform, $34 target +14.87%
- Inotek Pharmaceuticals Corp (RCKT) +12.36%
- Oric Pharmaceuticals Inc (ORIC) -16.12%
- Olema Pharmaceuticals Inc (OLMA) -23.85%
- DHC Acquisition (BNAI) -25.82%
Small caps were led by financing announcements, analyst initiations and FDA-related commentary where specifically noted. The group displayed wide dispersion, with several double-digit percentage moves in both directions.
What this session highlights
- Movements were largely driven by company-specific news: analyst upgrades, corporate financing and trial outcomes were recurrent catalysts.
- Technology and semiconductor-related names showed strength, while several major financial and legacy tech companies moved lower.
- Biotech and small-cap stocks reacted strongly to clinical and financing updates.
Market participants should note that the day’s activity reflected a mix of sector-specific news and individual company developments rather than a single, market-wide catalyst.